



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

14th February 2022

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001.
Scrip Code: 524816

Manager – Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400 051.
Scrip Code: NATCOPHARM

Dear Sir,

Sub:- Outcome of Board Meeting

Further to our intimation letter dated 5th February, 2022, we would like to inform you that the Board of Directors of the Company at their meeting held on today have approved the following along with other items of business:

1. Please find enclosed unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2021 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations ") along with Limited Review Report of the Statutory Auditors.
2. Declared 3rd interim dividend of Rs.2/- (Rupees one only) each per Equity share of Rs.2/- (Rupees two only) each for the financial year 2021-22 (which is 100% on the nominal value of the equity share). The date for taking on record of its shareholders eligible for the purpose of payment of third interim dividend i.e. record date is fixed as **Friday, the 25th February 2022**. The payment of said interim dividend will start from 4th March 2022.
3. Sri G S Murthy, Independent Director of the Company has been appointed as Chairman of the Company with effect from 1st April 2022.
4. Appointed / Re-appointed the following working Directors of the Company for a period of two year from 1st April 2022 to 31st March 2024 subject to the approval of the members of the Company by way of Postal Ballot. Brief profile of the below mentioned Directors is enclosed as annexure :

Name of the Director	DIN Number	Designation
Sri V C Nannapaneni	00183315	Managing Director
Sri Rajeev Nannapaneni	00183872	Director & CEO
Sri P S R K Prasad	07011140	Director & Executive Vice President Corp Engineering Services
Dr. D Linga Rao	07088404	Director & President (Technical Affairs)

5. Approved the Postal Ballot notice for seeking consent of the Shareholders for appointment/re-appointment of Sri V.C. Nannapaneni, Managing Director, Sri Rajeev Nannapaneni, Chief Executive Officer, Sri P.S.R.K. Prasad, Director and Executive Vice President (Corporate Engineering Services) and Dr. D. Linga Rao, Director and President (Tech. affairs) for a period of two (2) years i.e., from 1st April 2022 to 31st March 2024.

M. Linga Rao





Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

--:2--

6. Sri Sridhar Sankararaman, Non-Executive Non Independent Director of the Company has resigned from the Directorship of the company with effect from 15th February, 2022 due to his professional obligations and other pre occupations.
7. The Board of Directors had reconstituted the following Committees of the Directors of the company with effect from 15th February 2022:

Audit Committee

Sl. No.	Name of the Director
1	Sri G.S. Murthy, Independent Director
2	Sri T. V. Rao, Independent Director
3	Sri D. G. Prasad, Independent Director
4	Dr. M.U.R. Naidu, Independent Director

Nomination and Remuneration Committee

Sl. No.	Name of the Director
1	Sri G.S. Murthy, Independent Director
2	Dr. M.U.R. Naidu, Independent Director
3	Sri T. V. Rao, Independent Director

We hereby confirm that all the above-mentioned Appointed / Re-appointed Directors are not debarred from holding the office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such authority.

Please find attached herewith the Press Release in this regard.

We are also updating the financial results of the company on our website.

This is for your information and records.

Meeting commenced at 11.30 a.m. and concluded at 4.30 p.m.

Thanking you

Yours faithfully
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)

Encl: as above